Table 1.

Patient characteristics

Sex (%)
 Male47 (61.8)
 Female29 (38.2)
Age, mean years (range)62.5 (21–88)
 Age ≥65 years, number (%)22 (28.9)
Age at diagnosis, mean years (range)55.5 (17–83)
Complete blood count at diagnosis, mean value (range)
 White cell count × 109/L24 (8.2–290)
 Hemoglobin g/L13.6 (5.6–16.8)
 Platelet count × 109/L495 (106–2032)
Sokal risk group, number (%)
 Low39 (51.3)
 Intermediate24 (31.6)
 High10 (13.2)
 Unknown3 (3.9)
First-line TKI, number (%)
 Imatinib30 (39.5)
 Dasatinib35 (46.1)
 Nilotinib11 (14.5)
Second-line TKI, number (%)
 Dasatinib24 (31.6)
 Nilotinib9 (11.8)
 Bosutinib3 (3.9)
Third-line TKI, number (%)
 Dasatinib5 (6.6)
 Nilotinib2 (2.6)
 Median follow-up, years (range)4.9 (0.7–14.6)